Skip to main content

Advertisement

SpringerLink
Log in

Multiple effects of transfection with interleukin 2 and/or interferon γ on the behavior of mouse T lymphoma cells

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

We have previously reported that transfection of mouse interferon γ (IFN-γ) in H-2K k -positive BW vari-ants (BW-Sp3) abolishes tumorigenicity and reduces metastatic capacity. To further increase the immuno-genicity of BW-Sp3 cells, the gene for human interleukin 2 (huIL-2) was transfected in these cancer cells. Single BW-Sp3(huIL-2) and double BW-Sp3(huIL-2+IFN-γ) transfectants were generated and their behavior was investigated as compared to parental and IFN-γ-transfected BW-Sp3. Although expression of huIL-2 was equally effective as IFN-γ in preventing tumor formation and reducing experimental metastasis, it did not confer protection to spontaneous metastases and even reversed the anti-metastatic activity of IFN-γ. Inoculation of the BW variants in immunocompromised mice revealed that expression of IL-2 activates both T cells and aspecific immune effectors. However, in immunocompromised mice a clear pro-metastatic effect of IL-2 was recorded. Analysis of membrane antigens on the different variants showed a selective effect of huIL-2 on the expression of two surface antigens, i.e. L-selectin and metastatic T cell hybridoma antigen (MTH), which may contribute to metastasis. Hence upon expression of huIL-2 in T lymphoma variants, tumor outcome will depend on the balanced effects of the transfected cytokines on the immune response and the redirected effect on tumor progression. © Rapid Science Ltd.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Apte RN, Douvdevani A, Zöller M, et al. 1994, Cytokine-induced tumor immunogenicity: endogenous interleukin-1α expressed by fibrosarcoma cells confers reduced tumorigenicity. Immunol Lett, 39, 45-52.

    Article  Google Scholar 

  2. Fearon ER, Pardoll DM, Itaya T, et al. 1990, Interleukin-2 production by tumor cells bypasses T helper function in the generation of antitumor response. Cell, 60, 397-403.

    Article  PubMed  CAS  Google Scholar 

  3. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R and Gilboa E, 1990, Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med, 172, 1217-24.

    Article  PubMed  CAS  Google Scholar 

  4. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM and Frelinger JG, 1993, Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res, 53, 2112-17.

    PubMed  CAS  Google Scholar 

  5. Tepper RI, Pattengale PK and Leder P, 1989, Murine interleukin 4 displays potent antitumor activity in vivo. Cell, 57, 503-12.

    Article  PubMed  CAS  Google Scholar 

  6. Porgador A, Tzehoval E, Katz A, et al. 1992, Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res, 52, 3679-86.

    PubMed  CAS  Google Scholar 

  7. Aoki T, Tashiro K, Miyatake S-I, et al. 1992, Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Nat Acad Sci, U.S.A., 89, 3850-4.

    Article  CAS  Google Scholar 

  8. Richter G, Krüger-Krasagakes S, Hein G, et al. 1993, Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res, 53, 4134-7.

    PubMed  CAS  Google Scholar 

  9. Tahara H, Zeh HJ, Storkus WJ, et al. 1994, Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res, 54, 182-9.

    PubMed  CAS  Google Scholar 

  10. Raes G, Geldhof A, VandenDriessche T, Opdenakker G, Sibille C and De Baetselier P, 1995, Immunogenization of a murine T-cell lymphoma via transfection with interferon-gamma. Leukemia, 9,Suppl. 1:S121–S127.

    PubMed  Google Scholar 

  11. Porgador A, Bannerji R, Wanatabe Y, Feldman M, Gilboa E and Eisenbach L, 1993, Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene inserted tumor cells. J Immunol, 150, 1458-70.

    PubMed  CAS  Google Scholar 

  12. Blankenstein T, Qin Z, Uberla K, et al. 1991, Tumor suppression after tumor cell-targeted tumor necrosis α gene transfer. J Exp Med, 173, 1047-52.

    Article  PubMed  CAS  Google Scholar 

  13. Dranoff G, Jaffee E, Lazenby A, et al. 1993, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting antitumor immunity. Proc Nat Acad Sci, U.S.A., 90, 3539-43.

    Article  CAS  Google Scholar 

  14. Stoppacciaro A, Melani C, Parenza M, et al. 1993, Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte T-cell cooperation and T cellproduced interferon ?. J Exp Med, 177, 151-61.

    Article  Google Scholar 

  15. Allione A, Consalvo M, Nanni P, et al. 1994, Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL) 2, IL 4, IL 6, IL 7, IL 10, tumor necrosis factor α, granulocyte macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res, 54, 6022-6.

    PubMed  CAS  Google Scholar 

  16. VandenDriessche T, Verschueren H and De Baetselier P, 1991, Association between MHC class I antigen expression and malignancy of murine T lymphoma variants. Invasion and Metastasis, 10, 65-85.

    Google Scholar 

  17. VandenDriessche T, Bakkus M, Toussaint-Demylle D, Thielemans K, Verschueren H and De Baetselier P, 1994, Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens. Clin Exp Metastasis, 12, 73-83.

    Article  PubMed  CAS  Google Scholar 

  18. VandenDriessche T, Geldhof A, Bakkus M, et al. 1994, Metastasis of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Dk antigens. Int J Cancer, 58, 217-25.

    Article  PubMed  CAS  Google Scholar 

  19. Van Hecke D, Verschueren H and De Baetselier P, 1990, Identification of T-cell differentiation antigens, expressed on metastatic T-cell hybridomas and lymphomas. Int J Cancer, 45, 773-82.

    Article  PubMed  CAS  Google Scholar 

  20. Sibille C, Gould KG, Willard-Gallo K, et al. 1995, LMP2? proteasome are required for the presentation of specific antigens to cytotoxic T lymphocytes. Curr Biol, 5, 923-30.

    Article  PubMed  CAS  Google Scholar 

  21. Smith KA, 1990, Interleukin-2. Sci Am, 262, 50-7.

    Article  PubMed  CAS  Google Scholar 

  22. Heslop HE, Gottlieb DJ, Reittie JE, Bello-Fernandez C, Prentice HG and Brenner MK, 1989, Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. Br J Haematol, 72, 122-6.

    Article  PubMed  CAS  Google Scholar 

  23. Ralph P, 1973, Retention of lymphocyte characteristics by myelomas and theta+-lymphomas: sensitivity to cortisol and phytohemagglutinin. J Immunol, 110, 1470-5.

    PubMed  CAS  Google Scholar 

  24. De Baetselier P, Roos E, Brys L, Remels L and Feldman M, 1984, Generation of invasive and metastatic variants of a non-metastatic T-cell lymphoma by in vivofusion with normal host cells. Int J Cancer, 34, 731-8.

    Article  PubMed  CAS  Google Scholar 

  25. Verschueren H, Dekegel D and De Baetselier P, 1987, Development of a monolayer assay (MIA) for the discrimination and isolation of metastatic lymphoma cells. Invasion and Metastasis, 7, 1-15.

    CAS  Google Scholar 

  26. Geldhof AB, Vanden Driessche T, Opdenakker G and De Baetselier P, 1996, Introduction of the interferon ? gene into mouse T lymphoma cells with low MHC class I-expression results in selective induction of H-2Dkand concomitant enhanced metastasis. Cancer Immunol Immunother, 42, 329-38.

    Article  PubMed  CAS  Google Scholar 

  27. McMillan DN, Kernohan NM, Flett ME, et al. 1995, Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumor cells in situand in vitro: evidence for a direct role in the regulation of tumor cell proliferation. Int J Cancer, 60, 766-72.

    Article  PubMed  CAS  Google Scholar 

  28. Rubin BY and Gupta SL, 1980, Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proc Nat Acad Sci U.S.A., 77, 5928-32.

    Article  CAS  Google Scholar 

  29. Zier K, Gansbacher B and Salvadori S, 1996, Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today, 17, 39-45.

    Article  PubMed  CAS  Google Scholar 

  30. Pericle F, Kirken RA, Epling-Burnette PK, Blanchard DK and Djeu JY, 1996, Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int J Cancer, 66, 367-73.

    Article  PubMed  CAS  Google Scholar 

  31. Macdonald D, Jiang YZ and Swirsky D, 1991, Acute myeloid leukaemia relapsing following interleukin-2 treatment expresses the interleukin 2 receptor. Br J Haematol, 77, 43-9.

    Article  PubMed  CAS  Google Scholar 

  32. Ley K, Bullard DC, Arbonés ML, et al.1995, Sequential contribution of L-and P-selectin to leukocyte rolling in vivo. J Exp Med, 181, 669-75.

    Article  PubMed  CAS  Google Scholar 

  33. Shultz LD, Schweitzer PA, Christianson SW, et al. 1995, Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol, 154, 180-91.

    PubMed  CAS  Google Scholar 

  34. Richter G, Krüger-Krasagakes S and Hein G, 1993, Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res, 53, 4134-7.

    PubMed  CAS  Google Scholar 

  35. Rosenthal FM, Cronin K, Bannerji R, Golde DW and Gansbacher B, 1994, Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood, 83, 1289-98.

    PubMed  CAS  Google Scholar 

  36. Silagi S, Dutkowski R and Schaefer A, 1988, Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma. Int J Cancer, 41, 315-22.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cellular Immunology, Flanders Interuniversity Institute for Biotechnology, Free University of Brussels, Belgium

    Anja B. Geldhof, Jo Van Ginderachter, Pieter Vandersteen, Geert Raes & Patrick De Baetselier

Authors
  1. Anja B. Geldhof
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jo Van Ginderachter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pieter Vandersteen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Geert Raes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Patrick De Baetselier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Geldhof, A.B., Van Ginderachter, J., Vandersteen, P. et al. Multiple effects of transfection with interleukin 2 and/or interferon γ on the behavior of mouse T lymphoma cells. Clin Exp Metastasis 16, 447–459 (1998). https://doi.org/10.1023/A:1006585525399

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006585525399

Search

Navigation